Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beate Pfistner

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2003
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study GroupAndreas Engert, Petra Schiller, Andreas Josting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2007
Revised response criteria for malignant lymphomaBruce D Cheson, Beate Pfistner, Malik E Juweid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5Markus Sieber, Hans Tesch, Beate Pfistner, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2003
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study GroupAndreas Engert, Petra Schiller, Andreas Josting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2007
Revised response criteria for malignant lymphomaBruce D Cheson, Beate Pfistner, Malik E Juweid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5Markus Sieber, Hans Tesch, Beate Pfistner, et al.
Pageof 2